A systematic review of 1,000 screened records identified only three eligible studies examining administration timing for semaglutide, and none directly compared different days of the week or assessed tirzepatide timing.…

Catheter ablation for atrial fibrillation (AF) did not significantly improve AF-related quality of life compared with a sham procedure, despite reducing AF recurrence.

In a community-based trial in rural China, an intensive blood-pressure lowering intervention reduced the incidence of dementia compared with usual care, according to results from the China Rural Hypertension Control…

An editorial in Diabetology International argues that inappropriate GLP-1 use should be judged not only by regulatory compliance or off-label prescribing, but also by whether weight reduction is medically safe,…

In an exploratory study of 137 Australian adults, skin yellowness measured by reflectance spectroscopy was associated with combined fruit and vegetable intake, fruit intake alone, total carotenoid intake, body fat…

Remotely delivered exercise-based cardiac rehabilitation, when added to center-based programs, resulted in a similar number of completed sessions as center-based programs only, according to results presented in a Hot Line…

A rapid pathway for diagnosing heart attacks in the emergency department (ED) was as safe as a slower pathway but neither reduced the length of time patients spent in the…

Many breast cancer survivors whose treatment caused them to develop problems with their heart function can safely stop their medication after their heart recovers and most won't need to continue treatment long-term, according to a study funded by the British Heart Foundation and presented at the European Society of Cardiology…

Functional coronary angiography significantly reduced cardiovascular events and improved safety compared with conventional angiography in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.

Milvexian did not reduce major adverse cardiovascular events compared with placebo after a recent acute coronary syndrome and there was no increase in intracranial or fatal bleeding.